Pharma: Clinic Roundup
• UCB SA, of Brussels, Belgium, reported post-hoc analyses of pivotal trials of Neupro (rotigotine transdermal system) in patients with restless legs syndrome (RLS)/Willis Ekbom disease, showing improvements with rotigotine vs. placebo in most of the single items from the International RLS Study Group Rating Scale scores, which measured sensory-motor dysfunction, severity of sleep disturbance and the impact of RLS on daily activities. Those and other findings were presented at the American Academy of Neurology meeting in New Orleans.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter